Robust IL-2-dependent antitumor immunotherapy requires targeting the high-affinity IL-2R on tumor-specific CD8<sup>+</sup> T cells.

LaPorte, Kathryn M; Hernandez, Rosmely; Santos Savio, Alicia; Malek, Thomas R

Robust IL-2-dependent antitumor immunotherapy requires targeting the high-affinity IL-2R on tumor-specific CD8⁺ T cells.

LaPorte, Kathryn M; Hernandez, Rosmely; Santos Savio, Alicia; Malek, Thomas R.

Afiliação

LaPorte KM; Department of Microbiology and Immunology, University of Miami Miller School of Medicine, Miami, Florida, USA.
Hernandez R; Department of Microbiology and Immunology, University of Miami Miller School of Medicine, Miami, Florida, USA.
Santos Savio A; Department of Microbiology and Immunology, University of Miami Miller School of Medicine, Miami, Florida, USA.
Malek TR; Department of Microbiology and Immunology, University of Miami Miller School of Medicine, Miami, Florida, USA tmalek@med.miami.edu.

J Immunother Cancer ; 11(6)2023 06.

Article em En | MEDLINE | ID: mdl-37270181

Assuntos

Linfócitos T CD8-Positivos; Neoplasias; Camundongos; Animais; Neoplasias/tratamento farmacológico; Neoplasias/metabolismo; Linfócitos T Reguladores; Células Matadoras Naturais; Imunoterapia; Microambiente Tumoral

Palavras-chave

CD8-positive T-lymphocytes; cytokines; immune checkpoint inhibitors; immunotherapy; tumor microenvironment

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Linfócitos T CD8-Positivos / Neoplasias Limite: Animals Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google